PL1709014T3 - Przeciwcukrzycowe oksazolidenodiony i tiazolidenodiony - Google Patents

Przeciwcukrzycowe oksazolidenodiony i tiazolidenodiony

Info

Publication number
PL1709014T3
PL1709014T3 PL05722436T PL05722436T PL1709014T3 PL 1709014 T3 PL1709014 T3 PL 1709014T3 PL 05722436 T PL05722436 T PL 05722436T PL 05722436 T PL05722436 T PL 05722436T PL 1709014 T3 PL1709014 T3 PL 1709014T3
Authority
PL
Poland
Prior art keywords
thiazolidinediones
diones
diabetes
type
oxazolidinediones
Prior art date
Application number
PL05722436T
Other languages
English (en)
Inventor
Guo Q Shi
Peter T Meinke
James F Dropinski
Yong Zhang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PL1709014T3 publication Critical patent/PL1709014T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • C07D263/64—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings linked in positions 2 and 2' by chains containing six-membered aromatic rings or ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05722436T 2004-01-20 2005-01-18 Przeciwcukrzycowe oksazolidenodiony i tiazolidenodiony PL1709014T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53763004P 2004-01-20 2004-01-20
PCT/US2005/001344 WO2005070905A1 (en) 2004-01-20 2005-01-18 Antidiabetic oxazolidinediones and thiazolidinediones
EP05722436A EP1709014B1 (en) 2004-01-20 2005-01-18 Antidiabetic oxazolidinediones and thiazolidinediones

Publications (1)

Publication Number Publication Date
PL1709014T3 true PL1709014T3 (pl) 2007-10-31

Family

ID=34807112

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05722436T PL1709014T3 (pl) 2004-01-20 2005-01-18 Przeciwcukrzycowe oksazolidenodiony i tiazolidenodiony

Country Status (22)

Country Link
US (1) US20070173434A1 (pl)
EP (1) EP1709014B1 (pl)
JP (1) JP2007518803A (pl)
KR (1) KR20060128921A (pl)
CN (1) CN100451008C (pl)
AT (1) ATE363475T1 (pl)
AU (1) AU2005206540B2 (pl)
BR (1) BRPI0506919A (pl)
CA (1) CA2553405A1 (pl)
CY (1) CY1106757T1 (pl)
DE (1) DE602005001265T2 (pl)
DK (1) DK1709014T3 (pl)
ES (1) ES2287908T3 (pl)
IL (1) IL176878A0 (pl)
MX (1) MXPA06008190A (pl)
NO (1) NO20063720L (pl)
NZ (1) NZ548556A (pl)
PL (1) PL1709014T3 (pl)
PT (1) PT1709014E (pl)
RU (1) RU2355682C2 (pl)
WO (1) WO2005070905A1 (pl)
ZA (1) ZA200605512B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138328A1 (en) * 2005-06-14 2006-12-28 Merck & Co., Inc. Process for the production of antidiabetic oxazolidinediones
AU2006269503A1 (en) 2005-07-06 2007-01-18 Merck & Co., Inc. Antidiabetic oxazolidinediones and thiazolidinediones
CA2612984A1 (en) * 2005-07-20 2007-02-15 Merck & Co., Inc. Antidiabetic oxazolidinediones and thiazolidinediones
WO2008096769A1 (ja) * 2007-02-08 2008-08-14 Daiichi Sankyo Company, Limited 置換されたセルコスポラミド誘導体を含有する医薬
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
AU2019282727A1 (en) 2018-06-06 2020-11-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
MX2020013567A (es) 2018-06-14 2021-05-27 Poxel Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes.
CN111892569A (zh) * 2019-05-05 2020-11-06 石家庄圣泰化工有限公司 4,4’-联-1,3-二氧戊环-2,2’-二酮的合成方法
CN112898265A (zh) * 2019-11-18 2021-06-04 石家庄圣泰化工有限公司 4,4’-联-1,3-二氧戊环-2,2’-二酮的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
WO1999032465A1 (en) * 1997-12-19 1999-07-01 Merck & Co., Inc. Arylthiazolidinedione derivatives
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase

Also Published As

Publication number Publication date
BRPI0506919A (pt) 2007-06-05
IL176878A0 (en) 2006-10-31
RU2355682C2 (ru) 2009-05-20
PT1709014E (pt) 2007-08-13
DK1709014T3 (da) 2007-09-10
AU2005206540B2 (en) 2009-01-08
KR20060128921A (ko) 2006-12-14
US20070173434A1 (en) 2007-07-26
ES2287908T3 (es) 2007-12-16
NZ548556A (en) 2009-03-31
JP2007518803A (ja) 2007-07-12
WO2005070905A1 (en) 2005-08-04
MXPA06008190A (es) 2006-08-31
DE602005001265D1 (de) 2007-07-12
EP1709014A1 (en) 2006-10-11
AU2005206540A1 (en) 2005-08-04
RU2006129930A (ru) 2008-02-27
CA2553405A1 (en) 2005-08-04
ZA200605512B (en) 2007-11-28
CN100451008C (zh) 2009-01-14
CN1910163A (zh) 2007-02-07
NO20063720L (no) 2006-10-09
ATE363475T1 (de) 2007-06-15
EP1709014B1 (en) 2007-05-30
DE602005001265T2 (de) 2008-01-31
CY1106757T1 (el) 2012-05-23

Similar Documents

Publication Publication Date Title
IL176878A0 (en) Antidiabetic oxazolidinediones and thiazolidinediones
WO2004066963A3 (en) N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
WO2006014262A3 (en) Indoles having anti-diabetic activity
WO2004019869A3 (en) Indoles having anti-diabetic activity
CA2495943A1 (en) Indoles having anti-diabetic activity
WO2007018956A3 (en) Antidiabetic oxazolidinediones and thiazolidinediones
ZA914188B (en) Oxa-and thiazolidinedione hypoglycemic and hypocholesterolemic agents
NI200700200A (es) Compuestos aromáticos fusionados con actividad anti-diabética
MX2008011123A (es) Benzotiazoles que tienen actividad de receptor h3 de histamina.
ATE421490T1 (de) Verwendung von polymerpulver in pflasterfugenmörteln
NZ535684A (en) Use of a GLP-1 (glucagon like peptide-1) compound to treat gastroparesis by increasing gastric emptying
BR0211414A (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas
WO2006022954A3 (en) Benzoureas having anti-diabetic activity
ATE515494T1 (de) Neue verbindungen, deren herstellung und verwendung
WO2004037776A3 (en) Novel compounds and their use as prar-modulators
ES2123562T3 (es) Procedimiento para la preparacion de (s)-4-(3-(5-metil-2-fenil-4-oxazolil)-1-hidroxipropil)bromobenceno.
AU2003278814A1 (en) Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof
DE602005024539D1 (de) Neue verbindungen, ihre herstellung und verwendung
Sewter et al. PPARγ and the thiazolidinediones: molecular basis for a treatment of ‘Syndrome X’?
DE602005022585D1 (de) Phenoxyessigsäurederivate als ppar-agonisten
RS50136B (sr) Derivati tiazolidindiona i njihova upotreba kao antidijabetika
RS50137B (sr) Nova so 5-/4-/2-(n-metil-n-(2-piridil) amino)etoksi/benzil/ tiazolidin-2,4-dion hidrohlorid monohidrat
MY139550A (en) Indoles having anti-diabetic activity
AU2003246187A1 (en) MEDICINAL COMPOSITION CONTAINING DIURETIC AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) Gamma ACTIAVTOR
MY132008A (en) Bicyclic oxazole and thiazole substituted ethers